Syenza

Syenza™ is a life science consultancy for accelerating access to innovative healthcare technologies. Founder: @joaocarapinha

[Syenza @Syenza_Corp]

Key takeaway: EMA CHMP demands high-quality evidence for complex approvals to protect patients. https://t.co/oh8I7E6Ja7

[Syenza @Syenza_Corp]

EMA CHMP reviewed new medicines, biosimilars and extensions while rejecting several advanced therapies and revoking one product over trial concerns. The outcomes show what developers must demonstrate for approval. 📋

[Syenza @Syenza_Corp]

Sponsors should prepare robust datasets showing clear clinical benefit over risk. Using formal re-examination pathways with extra supporting data can refine indications and reverse initial refusals, as seen with the Rett syndrome treatment. ✅

[Syenza @Syenza_Corp]

One-time satri-cel therapy can ease resource use and support assessments in Asia while trials expand to earlier lines. https://t.co/hnvPUEutgw

[Syenza @Syenza_Corp]

A new CAR T therapy called satri-cel has gained approval as the first for any solid tumor. It focuses on Claudin18.2-positive gastric or gastroesophageal junction cancer after two prior treatments. Learn about its trial results and regional value next. 🧬

[Syenza @Syenza_Corp]

Satri-cel uses engineered T cells with a humanized fragment, CD28 domain, and a preconditioning mix of low-dose nab-paclitaxel plus lymphodepletion. This supports infiltration and yields survival gains in phase 2 trials with manageable safety for later-line use. 💡

[Syenza @Syenza_Corp]

Key takeaway: faster, fairer access needs less duplication, stronger national coordination, and better digital systems. Portugal has the building blocks; now it needs execution. https://t.co/UVQA3VvxiO

[Syenza @Syenza_Corp]

Portugal’s slow access to innovative therapies is costing patients time, health, and equality of care. Here’s what’s going wrong, why it matters, and what could improve access. 🧵

[Syenza @Syenza_Corp]

The article points to practical fixes: use joint European HTA reviews, approve SiNATS and SIATS, centralize pricing decisions, expand digital tracking, and use unified health records to identify eligible patients faster for trials and care.💡

[Syenza @Syenza_Corp]

Key takeaway: OTC glucose monitoring for children could improve awareness and support value-based pediatric care—but success depends on smart use, supervision, and thoughtful reimbursement. https://t.co/EXmXynvIC5

[Syenza @Syenza_Corp]

The FDA has cleared the first OTC continuous glucose monitor for children 2+ who don’t use insulin—giving families near real-time glucose insights while raising important questions about safety, supervision, and access. 📈

[Syenza @Syenza_Corp]

What helps? Use combined clinical + real-world data to speed safe approvals, give caregivers clear training on wear and skin checks, and guide higher-risk children to clinicians before use. That keeps access practical without overlooking safety. ✅